CATALYSTYahoo Finance • 11h ago
Freenome Soars 11% on Launch of Lung Cancer Blood Test That Makes Screening “Vastly Easier”Yahoo Finance report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
Why FRNM Stock dropped -2.95% Today — RQD Quant Desk Flash
$12.48 -2.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $12.39
Freenome Inc. (FRNM) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $1.38B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on FRNM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is FRNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Freenome Inc. (NASDAQ: FRNM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $12.48 (-2.95% 1D, market cap $1.38B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FRNM ranks #627 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does FRNM compare to TRUP and CSTL in the Health Care sector?
▼
Within the Health Care sector (Medical Specialities), FRNM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -3.4%. By comparison, TRUP (Trupanion Inc.) holds a C grade (63/100 RQD, P/E 68.2x, ROIC 3.1%, cap $1.32B) and CSTL (Castle Biosciences Inc.) posts a C grade (63/100 RQD, P/E N/A, ROIC -9.3%, cap $1.18B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for FRNM?
▼
Per FRNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002017526), Freenome Inc. generated $0 in revenue, $837.5K in net income, and -$864.7K in free cash flow against $92.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $12.39 (-0.72%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FRNM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY FRNM SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (33% of score)
FRED Regime × Technicals: 34% of 52W Range • RSI-14 at 43.3 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$13.22-4.9% Next Q
44
Q2 (-2Q)Grade D$12.57+1.2% Next Q
41
Q3 (-1Q)Grade E$12.72-1.9% Next Q
39
CurrentGrade D-$12.48-8.3% Hist 90D α
36
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a FRNM Turnaround Squeeze
While FRNM currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.72) and Max Pain ($13.10) forces dealer call-delta covering toward $18.38.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $FRNM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FRNM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why FRNM Stock dropped -2.95% Today — RQD Quant Desk Flash
Freenome Inc. (FRNM) dropped -2.95% to $12.48, trading at 34% of its 52-week range ($9.95 – $17.5). Stretched risk/reward at current multiples (-3% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 34% of its 52-week range ($9.95 – $17.5) with RSI-14 at 43.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $12.48 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live FRNM Headlines & Catalysts
MARKET WIREkalkine.ca • 14h ago
Why Is Freenome (NASDAQ:FRNM) Down 12.20% on a News Tag That Is Hard to Find?kalkine.ca report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 17h ago
Freenome, Inc. Estimates – NASDAQ:FRNMTradingView report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 20h ago
Cathie Wood’s ARK sells Alphabet stock, buys Freenome sharesInvesting.com report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 23h ago
Freenome (Nasdaq:FRNM) - Stock AnalysisSimply Wall St report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Eligible patients can be screened for lung and colorectal cancer with one blood draw.Stock Titan report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 1d ago
Cathie Wood’s ARK sells Personalised stock, buys Freenome sharesInvesting.com report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
abrdn Inc. reports a 0.61% Freenome (FRNM) stake held on behalf of underlying clients.Stock Titan report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 13d ago
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw – – In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and
MARKET WIREBenzinga • 13d ago
Freenome Unveils SimpleScreen Lung Enabling Patients To Be Screened For Lung And Colorectal Cancer Through Single Blood Draw, Using Two Independently Validated, Indication-Specific Tests– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw –– In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FRNM)
- ✓Walkthrough of FRNM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
FRNM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.93%📐 HORIZONTAL RANGE
2026-11-02O $13.44H $13.44L $12.48C $12.48VOL 360.3K
RES: $19.91SUP: $7.77SMA50: $14.72SMA200: $12.51
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
FRNM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on FRNM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for FRNM. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FRNM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FRNM)
Health Care Rank #627 of 1016
⚔️ TRUP vs FRNM Full Matrix →
1. Head-to-Head Health Care Peer Comparison (FRNM vs. TRUP, CSTL, ALHC, LMRI)
Industry: Medical Specialities (41 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Freenome Inc. (FRNM) ranks #627 by composite RQD confidence (36/100, grade D-) and #313 by equity capitalization ($1.38B). Within this direct 5-issuer industry benchmark cohort, TRUP leads on earnings valuation at 68.2x trailing P/E, while ALHC leads on capital efficiency and profitability with 13.9% ROIC and — gross margin. TRUP currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with FRNM at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| FRNM
ACTIVE
Freenome Inc. | D- | 36/100 | — | — | -3.4% | -2.95% | $1.38B | Benchmark Subject |
| TRUP Trupanion Inc. | C | 63/100 | 68.2x | 16.1% | 3.1% | -0.20% | $1.32B | /trup-vs-frnm → |
| CSTL Castle Biosciences Inc. | C | 63/100 | — | 79.4% | -9.3% | -3.51% | $1.18B | /cstl-vs-frnm → |
| ALHC Alignment Healthcare Inc. | D+ | 56/100 | — | — | 13.9% | -9.80% | $1.67B | /alhc-vs-frnm → |
| LMRI Lumexa Imaging Holdings Inc. | D+ | 54/100 | — | — | — | -2.73% | $1.13B | /lmri-vs-frnm → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002017526In its most recent audited fiscal period (FY2025, filed 2025-12-31), Freenome Inc. (FRNM) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $837.5K, operating cash flow of -$864.7K, and free cash flow of -$864.7K . On the balance sheet, FRNM closed FY2025 with $92.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $837.5K | -$864.7K | -$864.7K | $92.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $0 | — | — | $89.9M | — |
3. FRNM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs FRNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Freenome Inc. (NASDAQ: FRNM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $12.48 (-2.95% 1D, market cap $1.38B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FRNM ranks #627 in composite RQD confidence.
How does FRNM compare to TRUP and CSTL in the Health Care sector?
Within the Health Care sector (Medical Specialities), FRNM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -3.4%. By comparison, TRUP (Trupanion Inc.) holds a C grade (63/100 RQD, P/E 68.2x, ROIC 3.1%, cap $1.32B) and CSTL (Castle Biosciences Inc.) posts a C grade (63/100 RQD, P/E N/A, ROIC -9.3%, cap $1.18B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for FRNM?
Per FRNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002017526), Freenome Inc. generated $0 in revenue, $837.5K in net income, and -$864.7K in free cash flow against $92.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is FRNM trading relative to its 50-day, 200-day, and 52-week technical levels?
FRNM last traded at $12.48 (-2.95% on volume of 651,151 shares), positioning the stock -15.22% below its 50-day simple moving average ($14.72) and -0.24% below its 200-day simple moving average ($12.51). Across its 52-week range of $9.95 to $17.50, FRNM sits at the 33.5% percentile with a 14-day RSI of 43.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($10.92 to $14.04).
FRNM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is FRNM stock moving today?
Why FRNM Stock dropped -2.95% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-3% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 36/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
FRNM — Freenome Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:29:18Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, FRNM scores 36 out of 100 for a letter grade of D- and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The fundamental cash engine pillar scores 6 out of 20, reflecting ROIC of -3.4% and FCF yield of -0.06%; for an investor, this means the business is not currently generating returns on invested capital, so any valuation depends on expectations for future operating improvement rather than present cash generation. The whale 13F flow pillar scores 5 out of 20 and the insider conviction pillar scores 3 out of 20, indicating weak institutional and insider-linked support signals in the rating inputs. The macro regime fit pillar scores 12 out of 20, with beta of 1.0 and sector sensitivity noted, meaning the stock is rated as moving in line with the broader market rather than offering a defensive profile. The forensic balance sheet pillar scores 10 out of 20, reflecting Altman Z of 2.5, Piotroski F of 1/9, and Debt/Equity of 0.5. Upside drivers implied by the source data are limited to a potential turn in operating results and the recent news flow; the principal valuation tradeoff is that the stock trades without reported earnings-based multiples, so investors are pricing in future progress. This is an analytical framing, not personalized financial advice.
Business
Freenome Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Medical Specialities industry. Per the company profile, it operates in this industry with a market capitalization of $1.4B. Per the recent news wire, the company launched a lung cancer blood test positioned to make screening easier. The source data does not describe its customer base or detailed revenue model.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-3.0M | $0.8M | N/A | $-0.9M | N/A | N/A |
| FY 2024 | $0.0M | $0.0M | $0.0M | N/A | N/A | N/A | N/A |
Per the SEC financials, reported revenue is $0.0M in both periods and operating income is negative in FY 2025. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -3.4%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1/9, and Debt/Equity is 0.5. Balance sheet cash and debt values are not available in source data.
Recent Catalysts & News Wire Analysis
- Per the news wire, the sharpest headline reports the stock rising on the launch of a lung cancer blood test, flagged as a catalyst.
- Per the news wire, a separate report notes a decline of 12.20% on a news tag that is difficult to identify; this is flagged as a market wire item.
- Per the news wire, a report covers Cathie Wood's ARK buying Freenome shares.
- Per the news wire, a Stock Titan item notes that eligible patients can be screened for lung and colorectal cancer with one blood draw.
- Per the market data, the stock is down -4.32% at last price, on volume of 360311.
- Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are the reported cash and debt balances, given that these fields are N/A in the FY 2025 and FY 2024 filings?
- Why are FY 2025 net income ($0.8M) and operating income (-$3.0M) moving in opposite directions, and what drives the gap?
- What is the revenue trajectory, since reported revenue is $0.0M in both periods?
- Which institutional 13F holders and insider transactions exist, given that the holders section is empty?
- What is the commercial timeline and adoption path for the newly launched lung cancer blood test?
FRNM Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Freenome Inc. (FRNM) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 11h ago
Freenome Soars 11% on Launch of Lung Cancer Blood Test That Makes Screening “Vastly Easier” Yahoo Finance report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 14h ago
Why Is Freenome (NASDAQ:FRNM) Down 12.20% on a News Tag That Is Hard to Find? kalkine.ca report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 17h ago
Freenome, Inc. Estimates – NASDAQ:FRNM TradingView report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 20h ago
Cathie Wood’s ARK sells Alphabet stock, buys Freenome shares Investing.com report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 23h ago
Freenome (Nasdaq:FRNM) - Stock Analysis Simply Wall St report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Eligible patients can be screened for lung and colorectal cancer with one blood draw. Stock Titan report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
Cathie Wood’s ARK sells Personalised stock, buys Freenome shares Investing.com report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
abrdn Inc. reports a 0.61% Freenome (FRNM) stake held on behalf of underlying clients. Stock Titan report covering Freenome Inc. (FRNM) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
FRNM Bull vs. Bear Conversation Board — What's Your Call at $12.48?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FRNM 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $11.32 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is FRNM (D- • RQD 36/100) a Buy at $12.86?
Welcome to the FRNM (Freenome Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $9.77 (-24.0%)
Spot @ $12.86 Pump the brakes on FRNM — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on FRNM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Freenome Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $15.05 (+17.0%)
Spot @ $12.86 FRNM cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on FRNM, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $12.86 (52-wk range $9.95 - $17.50), any beat on forward guidance forces shorts and underweight funds to chase.